HB-EGF, Transactivation, and Cardiac Hypertrophy  by Takashima, Seiji & Kitakaze, Masafumi
International Journal of Gerontology | March 2007 | Vol 1 | No 12
■
© 2007 Elsevier.
Introduction
Signal transduction mediated by tyrosine kinase growth
factor receptor is one of the important pathways for cel-
lular proliferation. Many oncogenes are included in this
signal transduction, leading to the idea that inhibitors
of these signaling molecules can be used for cancer
therapy1. On the other hand, growth factor itself has
not been applied to clinical medicine for a long time
even though it has strong biologic activity. Growth fac-
tors have been thought to have deleterious effects for
promoting tumor formation and proliferation for clinical
use. However, these effects have recently been proven
to be minimal because of the downregulation of its
receptor, although several specific growth factors such
as erythropoietin and granulocyte colony-stimulating
factor have started to be used clinically, and their
effects were proved to be significant and remarkable2,3.
Thinking of their specificity and strong effects, growth
factors are expected to be used for further clinical
applications.
Neurons and cardiomyocytes are nonproliferative
cells; however, these cells are known to require growth
signals for their survival. In neurons, a substance called
neurotrophin is reported to be essential for their sur-
vival4; however, in cardiomyocytes, it is unknown what
signal is essential for their survival. Cardiomyocytes stop
their proliferation soon after birth and their number
does not change much throughout life5. This limited pro-
liferation ability causes difficulty in repair of heart mus-
cles after injuries such as ischemia-reperfusion injury.
We need to investigate how the proliferation and growth
of cardiomyocytes may be induced. Several investigators
including ourselves suggest that heparin-binding epider-
mal growth factor (EGF)-like growth factor (HB-EGF) is the
potential candidate for cell growth and wound healing.
In this review, we summarize the function of HB-
EGF, which is one of the EGF family of growth factors,
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especially for the metabolism of cardiomyocytes and
discuss the probability of the clinical application of HB-
EGF in heart failure.
HB-EGF and Signaling of ErbB 
Family Receptors
EGF growth factor family molecules including HB-EGF
have ErbB family as their receptors. The ErbB family of
receptor tyrosine kinases (RTKs) has fundamental roles
in development, proliferation, and differentiation of
various organs6. There are 4 members of the RTK ErbB
family, EGFR/ErbB1/HER1, ErbB2/HER2/neu, ErbB3/HER3,
and ErbB4/HER4. EGF family ligands bind to and acti-
vate their receptors by inducing the formation of either
homodimers or heterodimers, resulting in autophos-
phorylation of specific tyrosine residues within the cyto-
plasmic domain. The phosphorylated tyrosine residues
bind to the adapter proteins, which are instrumental in
mediating downstream signaling pathways that deter-
mine the biologic activity of EGF growth factor family
molecules.
In vertebrates, the EGF family of ligands binds to
ErbB receptors with some degree of preference. EGF,
transforming growth factor-α (TGF-α), and amphiregulin
bind to ErbB1; HB-EGF, epiregulin, and betacellulin bind
to both ErbB1 and ErbB4; NRG-1 (neuregulin/heregulin/
NDF) and NRG-2 bind to ErbB3 and ErbB4; NRG-3 and
NRG-4 bind to ErbB4 but not to ErbB3. Although no lig-
and for ErbB2 has yet been described, ErbB2 is active
as a signaling receptor by forming heterodimers with
other ErbB receptors7.
HB-EGF is synthesized as a type I transmembrane pro-
tein (proHB-EGF) composed of signal peptide, heparin-
binding, EGF-like, juxtamembrane, transmembrane,
and cytoplasmic domains8,9. The membrane-bound
proHB-EGF is cleaved at the juxtamembrane domain,
resulting in the shedding of soluble HB-EGF10. A similar
mechanism regulates other EGF family ligands and
determines the specific role at their target site11–13.
The full-length proHB-EGF is biologically active as 
a juxtacrine growth factor that transmits the signals 
to neighboring cells in a nondiffusible manner14–16.
ProHB-EGF forms complexes with CD917 on the cell
membrane. ProHB-EGF is also the receptor for diph-
theria toxin (DT), and mediates the entry of DT into the
cytoplasm18,19. Soluble HB-EGF is a potent mitogen and
chemoattractant for a number of cell types including
vascular smooth muscle cells (VSMCs), fibroblasts, and
keratinocytes20,21. HB-EGF has been implicated in many
physiologic and pathologic processes, which include
wound healing22,23, cardiac hypertrophy24, smooth
muscle cell hyperplasia25, kidney collecting duct mor-
phogenesis26, blastocyst implantation27, pulmonary
hypertension28, and oncogenic transformation29.
Gene-targeted mouse studies indicate that the ErbB
RTKs are critical for normal heart development. ErbB1
null mice with a CD1 background, and ErbB1 mutant
(waved-2) mice exhibit semilunar valve enlargement30.
ErbB2 null mouse embryos die from a defect in tra-
beculae formation31. The phenotype of ErbB4 knockout
mice is also embryonically lethal due to a similar
abnormal trabeculae formation as are mice lacking
NRG, the ErbB4 ligand32. Disruption of the ErbB3 gene
causes heart valve malformation, whereas trabeculae
formation is not affected33. The ErbB family is required
also for the maintenance of normal heart function in
the adult. Ventricle-specific conditional ErbB2 knockout
mice have severe heart failure with dilated ventricles
and decreased contractility function. These symptoms
resemble human dilated cardiomyopathy34,35. These
lines of evidence strongly suggest the tight relationship
between EGF growth factor signal and cardiac develop-
ment/metabolism.
HB-EGF and Cardiac Hypertrophy
The important role of HB-EGF on cardiomyocytes was
first disclosed by an accidental discovery during the
screening of metalloprotease inhibitors for drugs to
treat diabetic mice. One of the novel metalloprotease
inhibitors called KBR-7785 strongly inhibited cardiac
hypertrophy in vivo. KBR-7785 also inhibited cardiac
hypertrophy done by aortic banding of mice24. These
data suggested that metalloprotease activity is involved
in cardiac hypertrophy. At the same time, Prenzel et al.
reported that ErbB1 phosphorylation by endothelin
was mediated by cleaved HB-EGF through membrane-
anchored metalloprotease in tumor cells36. In this
report, metalloprotease inhibitor completely inhibited
ErbB1 phosphorylation by G protein coupled receptor
(GPCR) agonists such as endothelin or thrombin. They
concluded that GPCR agonists activated cell membrane
metalloprotease and cleaved HB-EGF and released HB-
EGF that binds to ErbB1. This ErbB1 phosphorylation by
GPCR agonists is called transactivation because GPCR
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agonists do not directly bind to ErbB1. The transacti-
vation of EGFR by GPCR agonists was first reported in
199637. However, it was surprising that this transacti-
vation was mediated by cleaved growth factor from
cell membrane. Since GPCR agonists were also known
to induce cardiac hypertrophy38, metalloprotease KBR-
7785 was thought to inhibit GPCR agonist-induced car-
diac hypertrophy by preventing cleavage of HB-EGF.
Substantial evidence indicates the existence of RTKs,
including ErbB1, in the heart24,35,39,40. Using rat neonatal
cardiomyocytes, EGFR phosphorylation by GPCR agonists
was examined and it was observed that HB-EGF phos-
phorylates its receptor (ErbB1). At the same time, GPCR
agonists phosphorylate ErbB1. This transactivation was
completely blocked by the metalloprotease inhibitor
KBR-7785 or neutralizing antibody for HB-EGF. Both
KBR-7785 and the neutralizing antibody for HB-EGF
also attenuated the hypertrophy of cardiomyocytes
mediated by either aortic banding or GPCR agonists 
in vivo. These data suggest that GPCR agonists utilize 
HB-EGF-mediated transactivation as a common pathway
for cardiac hypertrophy. Moreover, A disintegrin and
metalloprotease (ADAM) 12 was identified as a major
metalloprotease for HB-EGF cleaving in cardiomyo-
cytes24. This unique signaling mechanism is illustrated
in Figure 1. In this model, once extracellular stimuli are
incorporated into the cell, then the inside-out signal as
growth factor shedding occurs. Shedded growth factor
binds and activates EGFR from outside of the cell mem-
brane. This inside-out signaling seems rather ineffective;
however, this mechanism may be more plausible than
the intracellular transactivation of EGFR by GPCR ago-
nists. EGF ligands including HB-EGF bind to EGFR from
outside the cell membrane, and dynamically change the
conformation of EGFR, leading to the autophosphoryla-
tion of EGFR dimer41–43. Thinking of the necessity of
complex conformation change, activation of EGFR with-
out the ligand binding is rather unlikely. Instead, shed-
ding of membrane-anchored ligand is a more likely
mechanism of transactivation of EGFR after the stimula-
tion of GPCR. GPCR agonist regulates rapid response of
cell activity such as contractility mediated by transient
change of intracellular signal such as calcium44. Growth
signaling is a rather slow cellular response. EGFR trans-
activation may be a shearing mechanism to handle dif-
ferent cellular responses to GPCR agonists.
Phe
GPCR
Ang II ET-1
KBR-7785
HB-EGF
sHB-EGF
EGF
receptor
ADAM12
Cardiac hypertrophy
Cardiomyocyte survival?
Figure 1. G protein coupled receptor (GPCR) agonists activate membrane-anchored A disintegrin and metalloprotease (ADAM)
12, which is cleaved enzyme for membrane-anchored heparin-binding epidermal growth factor (EGF)-like growth factor (HB-
EGF). Cleaved HB-EGF binds and activates EGF receptor from outside of the cell membrane. Growth signal mediated by down-
stream signal such as ERK-1,2 induces cardiac hypertrophy. Metalloprotease inhibitor KBR-7785 inhibits ADAM12, resulting
in unsuccessful cleaving of HB-EGF from cell membrane after GPCR ligand stimulation.
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ErbB Receptor Transactivation and
Ectodomain Shedding of HB-EGF
Indeed, many of the mitogenic effects of GPCR ago-
nists are mediated through transactivation of EGFR.
Besides the heart, the inhibition of EGFR kinase using
the selective inhibitor AG1478 abolishes GPCR agonist-
mediated downstream signaling such as activation 
of ERK-1,2 in several cell types, including VSMCs and
cardiac myocytes45,46, and growth and migration of
VSMCs47. Thus, the transactivation of EGFRs by GPCRs
explains the majority of growth-promoting responses.
EGFR, an RTK, is endogenously expressed in numerous
cell types and is an important factor in the control of
many fundamental cellular processes, including cellu-
lar migration, metabolism, and survival, in addition to
cellular proliferation and differentiation48. RTKs pos-
sess an extracellular ligand-binding domain connected
to the cytoplasmic domain by a single transmembrane
helix. The cytoplasmic domain contains a conserved
protein kinase core and additional regulatory sequences
that are subjected to autophosphorylation and phos-
phorylation by other protein kinases49. Overexpression
of EGFR often results in uncontrolled growth and tissue
remodeling. Not surprisingly, EGFR and its ligands are
frequently upregulated in human cancers. Consequently,
blocking the proliferative effects of EGFR activation has
potential therapeutic applications in cancer and aber-
rant tissue growth. Then, a part of the effect of GPCR
agonists might be mediated by EGFR kinase activated
by truncated EGFR ligand family.
Ectodomain shedding of proHB-EGF is induced 
by various stimuli including phorbol esters, calcium
ionophore, and lysophosphatidic acid10,50,51. Multiple
signaling cascades such as the mitogen-activated pro-
tein kinase and protein kinase C pathways appear to
regulate HB-EGF shedding52,53. Metalloproteases were
implicated as the protease for shedding of proHB-
EGF since various metalloprotease inhibitors inhibited
ectodomain shedding of HB-EGF efficiently. Matrix met-
alloprotease (MMP) 3, MMP7, ADAM9, ADAM10, ADAM12,
and ADAM17 have been implicated as responsible pro-
teases24,53–57. The specific proteases involved in the
shedding process of HB-EGF depend on cell type and
biologic environment. For example, MMP7 appears 
to be involved in the shedding process in epithelial
cells, especially on the apical surface of cells. On the
other hand, ADAM12 seems to be responsible for HB-
EGF shedding in cardiomyocytes. Pro148-Val149 and
Glu151-Asn152 have been suggested as the shedding
sites of proHB-EGF54. Highly specific HB-EGF shedding
inhibitors have been found by a screening of hydrox-
amic acid-based compounds. They inhibit cutaneous
wound healing and cardiac hypertrophy in mice and
submandibular gland development in organ culture,
suggesting that ectodomain shedding of HB-EGF is
essential for various pathophysiologic processes and that
its inhibition might be a novel therapeutic strategy23,24.
Cardiac Phenotype of HB-EGF 
Gene-targeting Mouse
To further clarify the in vivo role of HB-EGF in cardiac
metabolism, a gene-targeting mouse of HB-EGF was
established. One of the HB-EGF gene aberrant mice
was designed to make a mouse in which HB-EGF was
not cleaved from cell membrane (HB-EGFuc/uc)58. An
uncleavable form of proHB-EGF was generated by cre-
ating double point mutations in the juxtamembrane
domain. HB-UC (a product of HBuc) was also resistant to
ectodomain shedding in response to various shedding-
inducing stimuli, while the other biologic properties of
HB-UC were similar to those of WT proHB-EGF. To assess
the biologic significance of proHB-EGF ectodomain
shedding, mutant mice expressing HB-UC instead of WT
proHB-EGF were also generated by targeted replace-
ment of the proHB-EGF gene with HBuc complementary
deoxyribonucleic acid. Homozygous mice (HBuc/uc)
were born at the predicted Mendelian frequency.
Northern blotting of the transcripts obtained from
adult mice indicated that the WT and HBuc alleles
were expressed equally in the heart, lung, and kidney.
Uncleavability of HB-EGF was also confirmed in vivo.
HB-EGFuc/uc has a relatively short life and showed
remarkable cardiac specific phenotype even though
HB-EGF was replaced by an uncleavable form in the
whole body. At 12 weeks, the hearts of HB-EGFpro/
pro mice were dilated and showed diminished move-
ment. Histologically, the cardiomyocytes of HB-EGFuc/uc
mice were degraded and replaced with fibrosis.
Echocardiography showed that the ejection fraction of
HB-EGFuc/uc mice was severely diminished. These
phenotypic changes are quite similar to human dilated
cardiomyopathy.
HB-EGF null mice (HB-EGFdel/del) were also pro-
duced by gene targeting and they showed similar heart
failure59. As with HB-EGFuc/uc mice, HB-EGF null mice
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showed obvious phenotype only in the heart, even
though HB-EGF was absent in the whole body. Although
studies of HBuc/uc mice indicated that ectodomain
shedding of proHB-EGF and release of sHB-EGF are
necessary for proper HB-EGF function in vivo, the
physiologic importance of the control of proHB-EGF
ectodomain shedding remains unclear.
To address this issue, another mouse mutant that
only expresses sHB-EGF was designed. The transmem-
brane domain-truncated mutant (HB tm) was gener-
ated by insertion of a stop codon in the major site for
proHB-EGF processing. Mitogenic activity was similar
between HB-TM (product of HB tm) and WT sHB-EGF
derived from proHB-EGF shedding, but HB-TM is secreted
at much higher levels than WT sHB-EGF. The targeting
construct for HB tm is similar to that for HBuc. One allele
of the proHB-EGF gene in embryo stem (ES) cells was
replaced with HB tm through homologous recombina-
tion. Chimeric mice carrying HB tm were generated
from these ES clones. Most chimeric founders exhibited
abnormally small bodies and thickened skin. Morpho-
logic abnormalities were also found in the heart of
HB tm mice. Histologic specimens showed ventricular
hypertrophy in hearts from HB tm E16.5 embryos. The
cardiac muscle fibers in chimeric mice were loose, with
enlarged nuclei. These results suggest that the expres-
sion of HB tm reduces cardiomyocyte differentiation
or terminates proliferation. These cardiac developmen-
tal abnormalities may be the primary cause of early
death in HB tm mice. The phenotype observed in HB
tm mice is likely due to deregulated secretion of sHB-
EGF. Under normal conditions, a portion of proHB-EGF
molecules is converted to sHB-EGF, but the majority of
proHB-EGF molecules on the cell surface seem to be
internalized without shedding10. In the case of HB tm,
most synthesized molecules would be secreted without
shedding, resulting in oversecretion of sHB-EGF even
though the native HB-EGF promoter regulates gene
expression. Therefore, deregulated secretion of sHB-EGF
would result in severe cardiac hypertrophy. The pres-
ent study thus confirms the notion that ectodomain
shedding of proHB-EGF must be strictly controlled 
in vivo. Also, HB-EGF is an important growth regulator
of cardiomyocytes. HB-EGF and its cleavage from cell
membranes are important not only for cardiac hyper-
trophy by GPCR agonists but also fundamental metab-
olism for cardiomyocytes. HB-EGF might have the role 
of a survival factor, like neurotrophin in neurons, by
exerting growth signal in cardiomyocytes.
EGFR in Cardiomyocytes and HB-EGF
Transactivation of ErbB1 by GPCR agonists was stated
above; however, there are 4 different subtypes of EGFRs
that exist genetically. To understand the precise physio-
logic roles of HB-EGF, it is essential to examine which
receptor subtypes are used in cardiomyocytes. Binding
affinity and capacity for phosphorylation of EGFRs are
different for each EGF family growth factor such as EGF
and TGF-α. HB-EGF can bind to ErbB1, 3, and 4 and
phosphorylates ErbB1, 2, and 3. ErbB4 is weakly 
phosphorylated by HB-EGF60. Since ErbB3 is rarely
expressed in cardiomyocytes, cardiac function medi-
ated by HB-EGF is mainly mediated by ErbB1, 2, and 4.
Indeed gene-targeting ErbB2 null mice showed the
severe cardiac phenotype35, suggesting that HB-EGF 
signal is partly mediated by ErbB2. Since ErbB2 does
not have physiologic ligands, ErbB2 forms heterodimer
with ErbB1 or 4. Therefore, ErbB2 is phosphorylated
by binding of EGF family growth factor to ErbB1 or 4.
In cardiomyocytes, HB-EGF can enhance the phospho-
rylation of ErbB1, 2, and 4. The in vivo phosphorylation
of HB-EGF null mice (HB-EGFdel/del) heart showed that
endogenous ErbB2 and 4 phosphorylation is attenu-
ated. We are now generating mice expressing receptor-
specific ligands in cardiomyocytes to rescue HB-EGF
null mice to clarify which EGFRs are important for cardiac
metabolism.
Future Clinical Application of HB-EGF
There is clinical evidence implying the important role
of HB-EGF in cardiac metabolism. Humanized anti-
body against ErbB2 (trastuzumab) is clinically used for
the treatment of advanced breast cancer all over the
world. In an early clinical trial, the combined therapy 
of trastuzumab with anthracycline worsened heart
function in 28% of patients61. Trastuzumab possibly
enhanced the cardiac toxicity of anthracycline. Since
ErbB2 is an important signaling molecule for HB-
EGF, blocking of ErbB2 signal by trastuzumab might
cause the impairment of HB-EGF signal, resulting in
the enhancement of cardiac toxicity. Anthracycline is
reported to induce cardiac toxicity by oxiradical. Car-
diomyocytes damaged by this oxiradical might require
more HB-EGF to maintain functional metabolism.
ErbB2 antibody trastuzumab is now prohibited for com-
bined use with anthracycline. In such cases, HB-EGF
administration could improve the cell damage. Also,
in case of other damage of cardiomyocytes such as
ischemia or myocarditis, HB-EGF could help in the recov-
ery of surviving cardiomyocytes. Growth factor therapy
still has some difficult aspects, especially concerning
tumor progression; however, its beneficial effect to tis-
sue is potent. Clinical trials using growth hormone or
insulin-like growth factor for heart failure is already in
progress62,63. We are still examining the biochemical
property of EGF signaling using HB-EGF-targeting mice,
seeking the possibility of growth factor therapy for
heart failure.
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